Tobira Therapeutics Inc. (TBRA) Lowered to “Hold” at Cantor Fitzgerald
Tobira Therapeutics Inc. (NASDAQ:TBRA) was downgraded by equities researchers at Cantor Fitzgerald from a “buy” rating to a “hold” rating in a research note issued on Wednesday.
Other analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Tobira Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Wednesday, July 13th. HC Wainwright reaffirmed a “buy” rating on shares of Tobira Therapeutics in a research report on Tuesday, June 28th. Finally, Cowen and Company reaffirmed a “buy” rating and set a $11.00 price objective on shares of Tobira Therapeutics in a research report on Wednesday, August 10th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Tobira Therapeutics has an average rating of “Buy” and a consensus target price of $16.75.
Shares of Tobira Therapeutics (NASDAQ:TBRA) opened at 38.91 on Wednesday. The company’s market capitalization is $732.33 million. Tobira Therapeutics has a 52-week low of $3.76 and a 52-week high of $41.39. The firm’s 50-day moving average is $5.61 and its 200 day moving average is $8.26.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/tobira-therapeutics-inc-tbra-lowered-to-hold-at-cantor-fitzgerald-2.html
Tobira Therapeutics (NASDAQ:TBRA) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.08. The firm had revenue of $1.06 million for the quarter. On average, equities research analysts anticipate that Tobira Therapeutics will post ($2.65) earnings per share for the current year.
In related news, major shareholder A/S Novo sold 92,119 shares of Tobira Therapeutics stock in a transaction on Thursday, July 7th. The shares were sold at an average price of $12.20, for a total value of $1,123,851.80. Following the completion of the sale, the insider now owns 2,016,691 shares of the company’s stock, valued at approximately $24,603,630.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 6.20% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of TBRA. Franklin Resources Inc. purchased a new position in Tobira Therapeutics during the first quarter worth about $4,797,000. State Street Corp increased its position in Tobira Therapeutics by 184.3% in the first quarter. State Street Corp now owns 42,875 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 27,794 shares in the last quarter. Geode Capital Management LLC increased its position in Tobira Therapeutics by 2.5% in the first quarter. Geode Capital Management LLC now owns 32,223 shares of the biopharmaceutical company’s stock worth $263,000 after buying an additional 799 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Tobira Therapeutics during the second quarter worth about $263,000. Finally, California State Teachers Retirement System increased its position in Tobira Therapeutics by 230.2% in the second quarter. California State Teachers Retirement System now owns 18,578 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 12,951 shares in the last quarter. 62.02% of the stock is currently owned by hedge funds and other institutional investors.
Tobira Therapeutics Company Profile
Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.
Receive News & Ratings for Tobira Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.